ArticleCancer cell2011
The spliceosome as an indicted conspirator in myeloid malignancies.
Article in Cancer cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Targeting TGFBR1 with the Investigational Inhibitor TP-6379 Improves Hematopoiesis in Low-Risk MDS Ex Vivo.Cells · 2026Article
- Research Progress on the Relationship Between PRPF8 and Cancer.Current issues in molecular biology · 2025Review
- Tyrosine kinase inhibitors induce alternative spliced BCR-ABLCancer science · 2020Article
- Proteomics-Based Evidence for a Pro-Oncogenic Role of ESRP1 in Human Colorectal Cancer Cells.International journal of molecular sciences · 2020Article
- Review
- Article
- SF3B1/Hsh155 HEAT motif mutations affect interaction with the spliceosomal ATPase Prp5, resulting in altered branch site selectivity in pre-mRNA splicing.Genes & development · 2016Article
- Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.Leukemia · 2016Article
- Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).Leukemia research · 2016Article
- The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.BMC cancer · 2015Article
- Prp40 pre-mRNA processing factor 40 homolog B (PRPF40B) associates with SF1 and U2AF65 and modulates alternative pre-mRNA splicing in vivo.RNA (New York, N.Y.) · 2015Article
- Stopping higher-risk myelodysplastic syndrome in its tracks.Current hematologic malignancy reports · 2014Review
- How mRNA is misspliced in acute myelogenous leukemia (AML)?Oncotarget · 2014Review
- The molecular basis of myeloid malignancies.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2014Review
- There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Current hematologic malignancy reports · 2013Review
- Standardizing the initial evaluation for myelodysplastic syndromes.Current hematologic malignancy reports · 2013Review
- The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.Molecular cancer research : MCR · 2013Review
- In vivo mutation of pre-mRNA processing factor 8 (Prpf8) affects transcript splicing, cell survival and myeloid differentiation.FEBS letters · 2013Article
- The spliceosome as a target of novel antitumour drugs.Nature reviews. Drug discovery · 2012Review
- New connections between splicing and human disease.Trends in genetics : TIG · 2012Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Reports of whole-exome sequencing in myelodysplastic syndrome (MDS) patients by Yoshida et al. and Papaemmanuil et al. suggest spliceosome mutations have clinical relevance. Identifying the impact of these mutations on MDS pathogenesis holds promise for therapeutic modulation of mRNA splicing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.